Digest Network Come funziona
Network
/
Società
Br
Non verificato

Bristol Myers Squibb

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

168 comunicati stampa

Guarda tutti i comunicati
29/10/2026
Biotecnologia
Salute
Scienza
Farmaceutica
Web e Social Network
Telefonia e Varie
Mercato azionario
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
26/10/2026
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
23/10/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
23/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mercato del lavoro
Eventi
Industria
Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
19/10/2026
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
12/10/2026
Scienza
Medicina nucleare
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Industria
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
12/10/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
08/10/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
01/10/2026
Biotecnologia
Salute
Associazioni/Professionisti
Farmaceutica
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
30/09/2026
Biotecnologia
Sanità
Igiene alimentare
Salute
Farmaceutica
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0